Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. (ORMP) generates news at the intersection of clinical-stage drug development, oral delivery technology, and strategic healthcare investments. The company describes itself as a platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, centered on its Protein Oral Delivery (POD™) technology and a refined oral insulin program.
News about Oramed often covers clinical and strategic milestones for its oral insulin and POD™ platform, including updates on trial design, analysis of Phase 2 and Phase 3 data, and plans for U.S.-based clinical studies. Company letters to shareholders and press releases provide context on how Oramed is advancing its oral insulin program independently and how it evaluates high-responder subgroups in its clinical data.
Another major source of headlines is Oramed’s investment and partnership activity across the biomedical and medical technology landscape. Releases have detailed structured financings and royalty arrangements with Scilex Holding Company, a substantial equity investment and strategic collaboration with Alpha Tau Medical Ltd., and positions in companies such as BioXcel Therapeutics Inc. and Pelthos Therapeutics Inc. These updates often discuss repayments, warrant structures, royalty interests, and unrealized gains.
Recent news also highlights transformative corporate transactions, such as the announced transfer of Oramed’s POD™ technology to Lifeward Ltd. in exchange for a significant beneficial ownership interest and participation in a revenue-generating medical robotics business. Additional items include stock repurchase programs, cash dividend declarations, and the adoption of a Rights Agreement involving common stock purchase rights.
Investors and followers of ORMP news can use this page to review Oramed’s press releases, shareholder letters, and transaction announcements in one place, tracking developments in its oral drug delivery platform, strategic investments, and corporate actions over time.
Oramed Pharmaceuticals announced positive feedback from the FDA during its End of Phase 2 meeting regarding its oral insulin, ORMD-0801. The FDA's feedback paves the way for Oramed to initiate two concurrent Phase 3 clinical trials after protocol review. Successful trials could lead to a Biologics License Application (BLA), which would grant 12 years of marketing exclusivity for ORMD-0801. The company aims to address unmet needs in diabetes treatment with this innovative oral insulin product.
Oramed Pharmaceuticals announced positive preliminary results from a pilot study on its oral insulin candidate, ORMD-0801, aimed at treating type 2 diabetes patients with non-alcoholic steatohepatitis (NASH). The study showed that ORMD-0801 was safe and well tolerated, with a mean reduction of 6.9% in liver fat content after 12 weeks. Additionally, significant decreases in gamma-glutamyltransferase and fasting insulin levels were observed. These findings were presented at the 80th American Diabetes Association Scientific Sessions, signaling potential for further research and clinical trials.